ScienceDex / Researcher record
Gause, Barry
- Leidos Biomedical Research, Inc. (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
- Early Career
NIH Funding · FY2023
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2021 | $950,000 | 1 | #9,953 |
| 2022 | $2,766,972 | 3 | #2,016 |
| 2023 | $429,747 | 1 | #27,397 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20211 record
- FY20223 records
- FY2023 · selected1 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2021 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award records by amount
NIH award records listing Gause, Barry as a PI. Multi-PI records show the full award amount for context.
- 75N91019D00024-P00012-759102000004-1N01Contact PITrial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Mpox Vaccine$429.7Kaward amount
Award organization
Organizations that administered FY2023 awards listing Gause, Barry as a PI.
FY2023 award administered by Leidos Biomedical Research, Inc. (MD).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2021First NIH AwardLeidos Biomedical Research, Inc.
- 2021$500K Cumulative Funding
- 2021Entered Top 50% NationallyRanked #9953
- 2022$1M Cumulative Funding
- 2022$2M Cumulative Funding
- 2022Entered Top 25% NationallyRanked #2016